The 18th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) meeting took place as a virtual event on the 24–25 September 2020.
The 2020 IOTOD Scientific Committee led an engaging two-day meeting, featuring international field experts speaking on multiple and emerging topics, such as: opioid analgesic dependence (OAD) and chronic pain; opioid substitution therapy adherence and the real significance; destigmatising drug use in key populations; the experience so far with long-acting buprenorphine formulations (and their use during COVID-19); different stakeholder perspectives surrounding drug use; and best approaches to address HCV/HBV in PWIDs. The webcasts from this conference will be available to view on the IOTOD 2021 conference platform once you have registered for the event.
Faculty
Dr Michael Kelleher
Consultant Addictions Psychiatrist, South London and Maudsley NHS Foundation Trust
London, UK
Professor Gabriele Fischer
Addictions Clinic Medical Director, Medical University of Vienna
Vienna, Austria
Nicholas Lintzeris
Drug and Alcohol Services, South-East Sydney Local Health District
Sydney, Australia
Graham Foster
Professor of Hepatology, Queen Mary's University of London & Consultant, Bart's Health NHS Trust
London, UK
Ashley Brown
Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, and Professor of Practice (Viral Hepatitis), Imperial College London
London, UK
Sponsors
The 2020 IOTOD conference is supported by the following companies:
Camurus
Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain.
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Session Sponsors
Indivior
Indivior is a global pharmaceutical company working to change patients’ lives by developing medicines to treat addiction and serious mental illnesses.
The medications Indivior provides play an essential role in treating opioid use disorder and addressing the opioid crisis.
Patient needs inspire us.
At the heart of Indivior is an unwavering commitment to support the patient journey to treatment and recovery, enable access to effective treatment, and provide education, new scientific understanding, and knowledge to the treatment community.
From the beginning, we have worked hard to destigmatize opioid use disorder by advocating that opioid use disorder to be recognized as a treatable medical condition, and not a moral failing.
We have an unrivaled track record for developing innovative medicines to treat opioid addiction.
Our Vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
